Xiaoyu Zhang1, Yong Wang2, Qiang Guo1, Yutao Diao1, Hongyan Liu1, Guanhua Song1, Wei Wang1, Zhiyong Zhang1, Haipeng Yin1, Lianlian Li3. 1. Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China. 2. Shandong Xinchuang Biotechnology Co., LTD, Jinan 250102, China. 3. Institute of Basic Medicine, Shandong Academy of Medical Sciences, Jinan 250062, China. Electronic address: lotuslee1985@126.com.
Abstract
BACKGROUND: Recent studies have shown that microRNA-155 (miR-155) is correlated with clinical outcomes of leukemia. This meta-analysis explores to evaluate the prognostic value of miR-155 for survival in patients with leukemia. METHODS: Eligible studies were searched from PubMed and EMBASE databases. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS), disease-free survival, event-free survival, progression-free survival and treatment-free survival were extracted, if available. Pooled HRs and 95% CIs were used to study any correlation between miR-155 and survival. RESULTS: 11 studies from 10 articles containing 1718 leukemia patients were included. Data showed that the pooled HR for OS was 1.67 (95% CI: 1.44-1.95, P < 0.01). Subgroup analyses for OS showed that the pooled HRs and their 95% CIs were 1.68, 1.41-2.00 (P < 0.01) and 1.73, 1.25-2.41 (P < 0.01) for acute myeloid leukemia and chronic lymphoblastic leukemia, respectively. Furthermore, there was no significant heterogeneity or publication bias among the enrolled datasets. CONCLUSION: We conclude that high miR-155 expression was associated with shorter OS for leukemia patients, and that miR-155 might be a promising prognostic biomarker for this patient population.
BACKGROUND: Recent studies have shown that microRNA-155 (miR-155) is correlated with clinical outcomes of leukemia. This meta-analysis explores to evaluate the prognostic value of miR-155 for survival in patients with leukemia. METHODS: Eligible studies were searched from PubMed and EMBASE databases. Hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) for overall survival (OS), disease-free survival, event-free survival, progression-free survival and treatment-free survival were extracted, if available. Pooled HRs and 95% CIs were used to study any correlation between miR-155 and survival. RESULTS: 11 studies from 10 articles containing 1718 leukemiapatients were included. Data showed that the pooled HR for OS was 1.67 (95% CI: 1.44-1.95, P < 0.01). Subgroup analyses for OS showed that the pooled HRs and their 95% CIs were 1.68, 1.41-2.00 (P < 0.01) and 1.73, 1.25-2.41 (P < 0.01) for acute myeloid leukemia and chronic lymphoblastic leukemia, respectively. Furthermore, there was no significant heterogeneity or publication bias among the enrolled datasets. CONCLUSION: We conclude that high miR-155 expression was associated with shorter OS for leukemiapatients, and that miR-155 might be a promising prognostic biomarker for this patient population.